Latest available resultsQuarter ended June 28, 202610-Q · July 23, 2026
Filed with the SECJOHNSON & JOHNSON
JNJPharma & biotech
Next reportOctober 13, 2026Analyst forecast 2.95 $/share
Revenue
$25.31B
▲ +6.6% vs prior year% YoY
Net income
$5.53B
▼ -0.1% vs prior year% YoY
EPS
2.27$
▼ -0.9% vs prior year% YoY
Net margin
21.9%
▼ -1.5 percentage points vs prior year pp YoY
Revenue▲ +6.6 %
Margins (% of revenue)GrossOperating N/ANet
Net income▼ -0.1 %
EPS▼ -0.9 %
View financial tableQuarter ended June 28, 2026
| Metric | Value | Context |
|---|---|---|
| Operations | ||
| Revenue | $25.31B | |
| Gross profit | $17.26B | 68.2 % |
| Operating income | — | |
| Net income | $5.53B | 21.9 % |
| R&D | — | |
| EPS (diluted) | 2.27 $ | |
| Balance sheet | ||
| Assets | $201.06B | |
| Liabilities | $116.09B | |
| Equity | $84.97B | |
| Cash | $20.42B | |
| Capital | ||
| Shares outstanding | 2.41B | as of 2026-07-17 |
| Public float | — | |